drugset / Trial / NCT04999449

Nebulizer Delivery of Intranasal Scopolamine

NCT04999449

Phase 1 Completed 14 enrolled Dartmouth-Hitchcock Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

To develop a better way to administer anti-motion sickness medications using an intranasal nebulizer.

Timeline

Start
2022-01-24
Primary completion
2025-05-07
Completion
2025-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Scopolamine Unknown 0.2 mg Intranasal
Subject Scopolamine Unknown 0.4 mg Intranasal

Indications